Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 27;9:25. doi: 10.1186/s40779-022-00383-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 3 — ROS accumulation blocks autophagosome degradation by activating the RIP1/RIP3 pathway after OGD/R. a Immunofluorescence images showing autophagy flux labeled by mRFP-GFP-LC3 in OGD/R-treated SH-SY5Y cells after NAC treatment (bar = 10 μm, n = 5/group). b Western blotting analysis and Co-IP assay showing RIP3 phosphorylation and RIP1-RIP3 binding ability in OGD/R-treated SH-SY5Y cells after NAC treatment (n = 8/group). c Western Blotting analysis and Co-IP assay showing RIP3 phosphorylation and RIP1-RIP3 binding ability in SH-SY5Y cells after Drp1 S616A mutation (n = 8/group). d Immunofluorescence images showing autophagy flux labeled by mRFP-GFP-LC3 in SH-SY5Y cells after Drp1 S616A mutation and Nec1 treatment (bar = 10 μm, n = 5/group). e Western Blotting analysis showing LC3 II/I ratio in SH-SY5Y cells after Drp1 S616A mutation and Nec1 treatment (n = 8/group). ^*P < 0.05, compared with normal group; ^#P < 0.05, compared with OGD/R or Drp1 S616A group; ^&P < 0.05, compared with OGD/R + NAC (1 mmol/L) or OGD/R + Nec1 (10 μmol/L) group. Co-IP co-immunoprecipitation, OGD/R oxygen–glucose deprivation/reoxygenation treatment, ROS reactive oxygen species